Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Julia M. K. Freind, Fernando R. Beserra, Bruno S. Menezes & Daniel C. Mograbi. (2023) Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review. Journal of Psychoactive Drugs 0:0, pages 1-17.
Read now
Read now
Debora Oliveira, Rodrigo Fontenele, Jeremy Weleff, Mehmet Sofuoglu & Joao P. De Aquino. (2023) Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review of Psychiatry 35:5-6, pages 377-396.
Read now
Read now
Carla Mendes Soares, Ângela Leite & Marta Pinto. (2023) Self-Care Practices with Psychedelics – A Qualitative Study of Users’ Perspectives. Journal of Psychoactive Drugs 55:2, pages 159-169.
Read now
Read now
Sandra J Drozdz, Akash Goel, Matthew W McGarr, Joel Katz, Paul Ritvo, Gabriella F Mattina, Venkat Bhat, Calvin Diep & Karim S Ladha. (2022) Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research 15, pages 1691-1706.
Read now
Read now
Nour Azhari, Helen Hu, Kate Y. O’Malley, Megan E. Blocker, Frances R. Levin & Elias Dakwar. (2021) Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study. The American Journal of Drug and Alcohol Abuse 47:1, pages 92-97.
Read now
Read now
Albert Garcia-Romeu & William A. Richards. (2018) Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30:4, pages 291-316.
Read now
Read now
Ricardo Jorge Dinis-Oliveira. (2017) Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sciences Research 2:1, pages 2-10.
Read now
Read now
Marie Claire Van Hout & Evelyn Hearne. (2015) “Word of Mouse”: Indigenous Harm Reduction and Online Consumerism of the Synthetic Compound Methoxphenidine. Journal of Psychoactive Drugs 47:1, pages 30-41.
Read now
Read now
Petr Winkler & Ladislav Csémy. (2014) Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia. Journal of Psychoactive Drugs 46:1, pages 11-19.
Read now
Read now
Brittany Vasae Burdick & Bryon Adinoff. (2013) A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. The American Journal of Drug and Alcohol Abuse 39:5, pages 291-297.
Read now
Read now
Paolo Mannelli, Kathleen S Peindl & Li-Tzy Wu. (2011) Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Substance Abuse and Rehabilitation 2, pages 113-123.
Read now
Read now
Jih-Heng Li, Balasingam Vicknasingam, Yuet-Wah Cheung, Wang Zhou, Adhi Wibowo Nurhidayat, Don C Des Jarlais & Richard Schottenfeld. (2011) To use or not to use: an update on licit and illicit ketamine use. Substance Abuse and Rehabilitation 2, pages 11-20.
Read now
Read now
Elias Dakwar & Frances R. Levin. (2009) The Emerging Role of Meditation in Addressing Psychiatric Illness, with a Focus on Substance Use Disorders. Harvard Review of Psychiatry 17:4, pages 254-267.
Read now
Read now
Articles from other publishers (86)
Lewis Leone, Bryan McSpadden, Annamarie DeMarco, Lauren Enten, Rachel Kline & Gregory A. Fonzo. (2024) Psychedelics and Evidence-based Psychotherapy. Psychiatric Clinics of North America 47:2, pages 367-398.
Crossref
Crossref
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles Saylor, George Danias, Lauren Lepow & Rachel Yehuda. (2024) The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Current Neuropharmacology 22:4, pages 636-735.
Crossref
Crossref
Agnieszka D. Sekula, Prashanth Puspanathan, Luke Downey & Paul Liknaitzky. (2024) Producing Altered States of Consciousness, Reducing Substance Misuse: A Review of Psychedelic-Assisted Psychotherapy, Transcendental Meditation and Hypnotherapy. Psychoactives 3:2, pages 137-162.
Crossref
Crossref
Viviana D. EvansAlejandro ArenasKenneth Shinozuka, Burton J. TabaacBryce D. BeutlerKirsten CherianChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine. American Journal of Therapeutics 31:2, pages e155-e177.
Crossref
Crossref
Vidette M. Juby, Saaeda Paruk, Mitsuaki Tomita & Bonga Chiliza. (2024) Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic. South African Journal of Psychiatry 30.
Crossref
Crossref
Marjorie R. Levinstein & Michael Michaelides. (2023) Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine. Neuropsychopharmacology 49:1, pages 315-316.
Crossref
Crossref
David B. Yaden, Andrea P. Berghella, Peter S. Hendricks, Mary E. Yaden, Michael Levine, Julia S. Rohde, Sandeep Nayak, Matthew W. Johnson & Albert Garcia-Romeu. (2024) IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research 199, pages 106998.
Crossref
Crossref
Nicholas Hovda, Winslow Gerrish, William Frizzell & Ryan Shackelford. (2024) A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders. Journal of Affective Disorders 345, pages 262-271.
Crossref
Crossref
Caryssa R. Drinkuth, Michael J. Lehane & Gregory C. Sartor. (2023) The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement. Drug and Alcohol Dependence 253, pages 110987.
Crossref
Crossref
Mary G. Hornick & Ashley Stefanski. (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
Simon Zhornitsky, Henrique N. P. Oliva, Laura A. Jayne, Aza S. A. Allsop, Alfred P. Kaye, Marc N. Potenza & Gustavo A. Angarita. (2023) Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. Frontiers in Psychiatry 14.
Crossref
Crossref
Marjorie R. Levinstein, Meghan L. Carlton, Tommaso Di Ianni, Emilya N. Ventriglia, Arianna Rizzo, Juan L. Gomez, Reece C. Budinich, Yavin Shaham, Raag D. Airan, Carlos A. ZarateJr.Jr., Jordi Bonaventura & Michael Michaelides. (2023) Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability. Biological Psychiatry 93:12, pages 1118-1126.
Crossref
Crossref
Mikhail L. Zobin. (2023) Ketamin in therapy of pharmacoresistent depressions in patients with double diagnosis (naturalistic study). Neurology Bulletin L:1, pages 15-20.
Crossref
Crossref
S. B. Thal, M. Wieberneit, J. M. Sharbanee, P. M. Skeffington, R. Bruno, T. Wenge & S. J. Bright. (2023) Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review. Journal of Humanistic Psychology.
Crossref
Crossref
Bess M. Kew, Richard J. Porter, Katie M. Douglas, Paul Glue, Charlotte L. Mentzel & Ben Beaglehole. (2023) Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review. BJPsych Open 9:3.
Crossref
Crossref
J.K.E. Veraart, M. van Westenbrugge, J.E. van Wulfften Palthe, A. van der Meij, R.A. Schoevers & J. de Jong. (2023) Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder. Heliyon 9:5, pages e15883.
Crossref
Crossref
Florence Jaguga, Philip Kirwa, Benson Gakinya, Imran Manji, Thomas Andale, Daniel Kinyanjui, Edith Kamaru Kwobah, Felicita Mwangi, Kituyi Werunga, Josephat Kerema, Charles Kwobah, Eunice Temet, Julia Songok & Wilson K. Aruasa. (2023) Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report. Substance Abuse Treatment, Prevention, and Policy 18:1.
Crossref
Crossref
C. Dauré & L. Mallet. 2023. Les Addictions. Les Addictions
593
599
.
Meryem Grabski & Celia Morgan. 2023. Encyclopedia of Mental Health. Encyclopedia of Mental Health
328
335
.
Reid Robison, Adele Lafrance, Madeline Brendle, Michelle Smith, Claire Moore, Sachin Ahuja, Scott Richards, Nicole Hawkins & Erin Strahan. (2022) A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders. Journal of Eating Disorders 10:1.
Crossref
Crossref
Christina Driver, Timothy N.W. Jackson, Jim Lagopoulos & Daniel F. Hermens. (2022) Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 119, pages 110609.
Crossref
Crossref
Arafath Mohamed, Shehla Touheed, Muzammil Ahmed, Mosab Hor & Sara Fatima. (2022) The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?. Cureus.
Crossref
Crossref
Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye & Alan D. Kaye. (2022) Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review. Health Psychology Research 10:4.
Crossref
Crossref
Sachin Ahuja, Madeline Brendle, Leo Smart, Claire Moore, Paul Thielking & Reid Robison. (2022) Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. BMC Psychiatry 22:1.
Crossref
Crossref
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, Felicia Ceban, Shakila Meshkat, Leanna M.W. Lui, Farhan Fancy, Joshua D. Rosenblat & Roger S. McIntyre. (2022) Active mechanisms of ketamine-assisted psychotherapy: A systematic review. Journal of Affective Disorders 315, pages 105-112.
Crossref
Crossref
Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J. Akiki, Alok Madan, Leonardo Vando, Kristin Arden, Jack Swain, Madeline Klotz & Casey Paleos. (2022) At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Journal of Affective Disorders 314, pages 59-67.
Crossref
Crossref
Nicolas Garel, Christina McAnulty, Kyle T. Greenway, Paul Lesperance, Jean-Philippe Miron, Soham Rej, Stephane Richard-Devantoy & Didier Jutras-Aswad. (2022) Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions.. Drug and Alcohol Dependence 239, pages 109606.
Crossref
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Crossref
Bradford Martins, Will Rutland, Joao P. De Aquino, Benjamin L. Kazer, Melissa Funaro, Marc N. Potenza & Gustavo A. Angarita. (2022) Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders. Current Addiction Reports 9:4, pages 647-659.
Crossref
Crossref
Snehal R. Bhatt, Maya Armstrong, Tassy Parker, Marcello Maviglia, Rebecca Kass, Lawrence Leeman, Paul Romo & Douglas Ziedonis. (2022) Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Frontiers in Pharmacology 13.
Crossref
Crossref
Mauro Cavarra, Alessandra Falzone, Johannes G. Ramaekers, Kim P. C. Kuypers & Carmela Mento. (2022) Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions. Frontiers in Psychology 13.
Crossref
Crossref
H. Bottemanne, A. Baldacci, C. Muller, A. Boyreau & A. Claret. (2022) Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi. L'Encéphale 48:3, pages 304-312.
Crossref
Crossref
David S. Mathai, Victoria Mora & Albert Garcia-Romeu. (2022) Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology 13.
Crossref
Crossref
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch & Kevin W. Morin. (2022) Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating Ketamine Protocols with Trauma- and Attachment-Informed Psychotherapy. Psych 4:1, pages 119-141.
Crossref
Crossref
Igor D. Bandeira, Daniel H. Lins-Silva, Vitor Breseghello Cavenaghi, Ingrid Dorea-Bandeira, Daniela Faria-Guimarães, Judah L. Barouh, Ana Paula Jesus-Nunes, Graziele Beanes, Lucca S. Souza, Gustavo C. Leal, Gerard Sanacora, Euripedes C. Miguel, Aline S. Sampaio & Lucas C. Quarantini. (2022) Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review of Psychiatry 30:2, pages 135-145.
Crossref
Crossref
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, Pratap Chokka, Martin A. Katzman, Robert L. Tanguay & Atul Khullar. (2022) Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. CNS Drugs 36:3, pages 239-251.
Crossref
Crossref
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt & Celia J. A. Morgan. (2021) Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8:1.
Crossref
Crossref
Annika Rosenthal, Claudia Ebrahimi, Friederike Wedemeyer, Nina Romanczuk-Seiferth & Anne Beck. (2022) The Treatment of Substance Use Disorders: Recent Developments and New Perspectives. Neuropsychobiology 81:5, pages 451-472.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold & Brian S. Fuehrlein. (2022) Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. Journal of the Neurological Sciences 432, pages 120094.
Crossref
Crossref
Mateusz Kowalczyk, Edward Kowalczyk, Paweł Kwiatkowski, Łukasz Łopusiewicz, Monika Sienkiewicz & Monika Talarowska. (2021) Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review. Life 11:11, pages 1186.
Crossref
Crossref
John Martin Corkery, Wan-Chu Hung, Hugh Claridge, Christine Goodair, Caroline S Copeland & Fabrizio Schifano. (2021) Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. Journal of Psychopharmacology 35:11, pages 1324-1348.
Crossref
Crossref
Joseph A. Clerke, Mauro Congiu & Manuel Mameli. (2021) Neuronal adaptations in the lateral habenula during drug withdrawal: Preclinical evidence for addiction therapy. Neuropharmacology 192, pages 108617.
Crossref
Crossref
Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso, Alessio Mosca, Andrea Miuli, Francesco Di Carlo, Giacomo D’Andrea, Roberta Collevecchio, Ilenia Di Muzio, Stefano L. Sensi & Massimo Di Giannantonio. (2021) Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sciences 11:7, pages 856.
Crossref
Crossref
Samuel Kohtala. (2021) Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacological Reports 73:2, pages 323-345.
Crossref
Crossref
Kabir B. Nigam & Ananda K. Pandurangi. (2021) Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature. SN Comprehensive Clinical Medicine 3:6, pages 1385-1395.
Crossref
Crossref
Ingmar Gorman, Elizabeth M. Nielson, Aja Molinar, Ksenia Cassidy & Jonathan Sabbagh. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Frontiers in Psychology 12.
Crossref
Crossref
Rebecca L Rothberg, Nour Azhari, Nancy A Haug & Elias Dakwar. (2020) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology 35:2, pages 150-158.
Crossref
Crossref
Elisabeth Hertenstein, Ersilia Trinca, Carlotta L. Schneider, Marina Wunderlin, Kristoffer Fehér, Dieter Riemann & Christoph Nissen. (2021) Augmentation of Psychotherapy with Neurobiological Methods: Current State and Future Directions. Neuropsychobiology 80:6, pages 437-453.
Crossref
Crossref
Jessica Lochtenberg, Ari Kirshenbaum & Matthew W. Johnson. (2021) Pharmacological assistance for psychotherapy. Emerging Trends in Drugs, Addictions, and Health 1, pages 100017.
Crossref
Crossref
Negar Zekri, Reza Fareghi-Alamdari & Behnaz Momeni-Fard. (2020) Synthesis of ketamine from a nontoxic procedure: a new and efficient route. Journal of Chemical Sciences 132:1.
Crossref
Crossref
Basant Pradhan & Garrett Rossi. (2020) Combining Ketamine, Brain Stimulation (rTMS) and Mindfulness Therapy (TIMBER) for Opioid Addiction. Cureus.
Crossref
Crossref
Mohammad Farris Iman Leong Bin Abdullah. (2020) Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature. Current Drug Targets 21:15, pages 1566-1579.
Crossref
Crossref
Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie & Eric Vermetten. (2020) Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology 23:6, pages 385-400.
Crossref
Crossref
Greer McKendrick, Hannah Garrett, Holly E. Jones, Dillon S. McDevitt, Sonakshi Sharma, Yuval Silberman & Nicholas M. Graziane. (2020) Ketamine Blocks Morphine-Induced Conditioned Place Preference and Anxiety-Like Behaviors in Mice. Frontiers in Behavioral Neuroscience 14.
Crossref
Crossref
Dimy Fluyau, Neelambika Revadigar & Christopher G. Pierre. (2020) Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review. Drug and Alcohol Dependence 208, pages 107845.
Crossref
Crossref
Agata Nowacka & Malgorzata Borczyk. (2019) Ketamine applications beyond anesthesia – A literature review. European Journal of Pharmacology 860, pages 172547.
Crossref
Crossref
Rémi Corne & Raymond Mongeau. (2019) Utilisation des psychédéliques en psychiatrie : lien avec les neurotrophines. Biologie Aujourd’hui 213:3-4, pages 121-129.
Crossref
Crossref
Esther Blessing, Sanya Virani & John Rotrosen. 2020. Substance Use Disorders. Substance Use Disorders
167
202
.
I. Ivan Ezquerra-Romano, W. Lawn, E. Krupitsky & C.J.A. Morgan. (2018) Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology 142, pages 72-82.
Crossref
Crossref
Edward.M. Sellers, Myroslava K. Romach & Deborah B. Leiderman. (2018) Studies with psychedelic drugs in human volunteers. Neuropharmacology 142, pages 116-134.
Crossref
Crossref
Jennifer L. Jones, Camilo F. Mateus, Robert J. Malcolm, Kathleen T. Brady & Sudie E. Back. (2018) Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry 9.
Crossref
Crossref
Eduardo Ekman Schenberg. (2018) Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology 9.
Crossref
Crossref
Tehseen Noorani, Albert Garcia-Romeu, Thomas C Swift, Roland R Griffiths & Matthew W Johnson. (2018) Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology 32:7, pages 756-769.
Crossref
Crossref
Christian Sueur. (2018) État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle. Psychotropes Vol. 23:3, pages 125-163.
Crossref
Crossref
Salih Selek & Jair C. Soares. 2018. Understanding Depression. Understanding Depression
269
275
.
Lantie Jorandby-Quinones, Ellen Edens & Robert A. Rosenheck. 2018. Military and Veteran Mental Health. Military and Veteran Mental Health
307
333
.
Jason Wallach & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
305
352
.
Michael P. Bogenschutz & Alyssa A. Forcehimes. (2016) Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism. Journal of Humanistic Psychology 57:4, pages 389-414.
Crossref
Crossref
Rafael G. dos Santos, José Carlos Bouso & Jaime E. C. Hallak. (2017) The antiaddictive effects of ibogaine: A systematic literature review of human studies. Journal of Psychedelic Studies 1:1, pages 20-28.
Crossref
Crossref
Brian M. Radvansky, Shawn Puri, Anthony N. Sifonios, Jean D. Eloy & Vanny Le. (2016) Ketamine—A Narrative Review of Its Uses in Medicine. American Journal of Therapeutics 23:6, pages e1414-e1426.
Crossref
Crossref
Yu Liu, Deyong Lin, Boliang Wu & Wenhua Zhou. (2016) Ketamine abuse potential and use disorder. Brain Research Bulletin 126, pages 68-73.
Crossref
Crossref
Zach Walsh, Peter S Hendricks, Stephanie Smith, David S Kosson, Michelle S Thiessen, Philippe Lucas & Marc T Swogger. (2016) Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology 30:7, pages 601-607.
Crossref
Crossref
Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi & Jaime E. C. Hallak. (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology 6:3, pages 193-213.
Crossref
Crossref
Faryal Mallick & Cheryl B. McCullumsmith. (2016) Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. Current Psychiatry Reports 18:6.
Crossref
Crossref
Ben Sessa & Friederike Meckel Fischer. (2015) Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary. Drug Science, Policy and Law 2, pages 205032451557808.
Crossref
Crossref
Keith G. Rasmussen. (2016) Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 218-224.
Crossref
Crossref
Ou Sha, Yue Hao, Eric Cho & Li Zhou. 2015. Ketamine. Ketamine
13
36
.
Tomislav Majić, Timo T Schmidt & Jürgen Gallinat. (2015) Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?. Journal of Psychopharmacology 29:3, pages 241-253.
Crossref
Crossref
Brian M. Radvansky, Khushbu Shah, Anant Parikh, Anthony N. Sifonios, Vanny Le & Jean D. Eloy. (2015) Role of Ketamine in Acute Postoperative Pain Management: A Narrative Review. BioMed Research International 2015, pages 1-10.
Crossref
Crossref
David E. Potter & Mahua Choudhury. (2014) Ketamine: repurposing and redefining a multifaceted drug. Drug Discovery Today 19:12, pages 1848-1854.
Crossref
Crossref
Peter S Hendricks, C Brendan Clark, Matthew W Johnson, Kevin R Fontaine & Karen L Cropsey. (2014) Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology 28:1, pages 62-66.
Crossref
Crossref
Ornella Corazza, Sulaf Assi & Fabrizio Schifano. (2013)
From “Special
K
” to “Special
M
”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
. CNS Neuroscience & Therapeutics 19:6, pages 454-460.
Crossref
Crossref
Ben Sessa. (2012) Shaping the renaissance of psychedelic research. The Lancet 380:9838, pages 200-201.
Crossref
Crossref
Michael P. Bogenschutz & Jessica M. Pommy. (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Testing and Analysis 4:7-8, pages 543-555.
Crossref
Crossref
Hylke Vervaeke. 2008. Drugs en alcohol; Gebruik, misbruik en verslaving. Drugs en alcohol; Gebruik, misbruik en verslaving
369
406
.
Francisca Charliane Carlos Da Silva, Rodrigo Tavares Dantas, Maria d do Carmo de Oliveira Citó, Silvânia Maria Mendes De Vasconcelos, Marta Maria de França Fonteles, Glauce Socorro de Barros Viana & Francisca Cléa Florenço De Sousa. (2001) Ketamina, da anestesia ao uso abusivo. Revista Neurociências 18:2, pages 227-237.
Crossref
Crossref